Zacks Analyst Blog Highlights Emergent BioSolutions, Chimerix and SIGA Technologies

0

For immediate release

Chicago, IL – May 23, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Emergent BioSolutions EBS, Chimerix CMRX and SIGA Technologies SIGA.

Here are highlights from Friday’s analyst blog:

Monkeypox fears driving makers of smallpox antivirals

Shares of companies like Emerging BioSolutions and SIGA Technologies, which caters to the biodefense market and manufactures drugs/vaccines to treat smallpox, rose on Thursday as fears of a monkeypox outbreak in Europe grew and a case was reported in the United States . Monkeypox is a rare but potentially serious viral illness with fever-like symptoms and rashes on the face and body.

Emergent BioSolutions stock rose nearly 12% while SIGA Technologies rose 17.1% on Thursday.

The monkeypox virus belongs to the same family of viruses that causes smallpox. Symptoms of monkeypox are similar to those of smallpox although less severe. In the United States, the case of monkeypox was confirmed in a man who had recently traveled to Canada. According to the United States Centers for Disease Control and Prevention, the current case of monkeypox does not pose a public health risk. Small outbreaks of monkeypox have been reported in some European countries like UK, Spain, Portugal, although this disease hardly appears in countries outside of Africa.

Emergent makes ACAM2000, a smallpox vaccine that could be used to treat monkeypox. Additionally, last week, Emergent announced an agreement with Chimerix to acquire exclusive worldwide rights to CMRX’s oral smallpox antiviral product, Tembexa. The FDA approved Chimerix’s Tembexa in June 2021. The transaction is expected to close as early as Q2 2022.

Increasing demand for the ACAM2000 vaccine and potentially Tembexa could help Emergent realize profits if the monkeypox infection spreads further.

SIGA Technologies manufactures an oral antiviral drug called Tpoxx ((tecovirimat), which is approved in the United States, Canada and Europe for the treatment of smallpox. Oral Tpoxx is also approved in Europe for the treatment of monkeypox. On Thursday, the FDA has approved an intravenous (IV) drug formulation of Tpoxx that will help SIGA Technologies meet the needs of a broader patient population.

Shares of Emergent BioSolutions are down 27.1% in the year to date, while shares of Siga Technologies are up 15%. the industry experienced a decrease of 24.9% during the said period, as shown in the table below.

Zacks Rank

Currently, Emergent BioSolutions has a Zacks rank of #5 (strong sell) while SIGA Technologies has a Zacks rank of 4 (sell).

You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. To visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.

5 shares ready to double

Each was handpicked by a Zacks expert as the #1 preferred stock to earn +100% or more in 2021. Previous recommendations have skyrocketed +143.0%, +175.9%, + 498.3% and +673.0%.

Most of the stocks in this report fly under the radar on Wall Street, which provides a great opportunity to get in on the ground floor.

Today, check out these 5 potential home runs >>

Click to get this free report

Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report

Siga Technologies Inc. (SIGA): Free Inventory Analysis Report

Chimerix, Inc. (CMRX): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Share.

Comments are closed.